The Library
Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
Tools
Tools
Tools
Feher, Michael D., Greener, Mark and Munro, Neil (2013) Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol.2013 (No.6). pp. 11-15. doi:10.2147/DMSO.S35053
|
Text
WRAP_Munro_DMSO-35053-persistent-hypertriglyceridaemia-in-statin-treated-patients-_010913.pdf - Published Version Download (311Kb) | Preview |
Official URL: http://dx.doi.org/10.2147/DMSO.S35053
Abstract
Purpose: This paper reports the results of an audit that assessed the prevalence of residual hypertriglyceridemia and the potential need for intensified management among patients with statin-treated type 2 diabetes mellitus (T2DM) in primary care in the UK.
Patients and methods: A cross-sectional, observational, systematic audit of patients with diagnosed diabetes from 40 primary care practices was undertaken. The audit collected basic demographic information and data on prescriptions issued during the preceding 4 months. T2DM patients were stratified according to the proportion that attained European Society of Cardiology treatment targets.
Results: The audit collected data from 14,652 patients with diagnosed diabetes: 89.5% (n = 13,108) of the total cohort had T2DM. Of the people with T2DM, 22.2% (2916) were not currently receiving lipid-lowering therapy. Up to approximately 80% of these people showed evidence of dyslipidemia. Among the group that received lipid-lowering therapy, 94.7% (9647) were on statin monotherapy, which was usually simvastatin (69.5% of patients receiving statin monotherapy; 6707). The currently available statins were prescribed, with the most common dose being 40 mg simvastatin (44.2%; 4267). Irrespective of the statin used, around half of the patients receiving statin monotherapy did not attain the European Society of Cardiology treatment targets for triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol.
Conclusion: T2DM patients managed in UK primary care commonly show persistent lipid abnormalities. Clinicians need to optimize compliance with lipid-lowering and other medications. Clinicians also need to consider intensifying statin regimens, prescribing additional lipid-modifying therapies, and specific treatments aimed at triglyceride lowering to improve dyslipidemia control in statin-treated patients with T2DM.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine | ||||
| Divisions: | Faculty of Medicine > Warwick Medical School | ||||
| Library of Congress Subject Headings (LCSH): | Hypertriglyceridemia, Non-insulin-dependent diabetes -- Treatment -- Complications, Statins (Cardiovascular agents) | ||||
| Journal or Publication Title: | Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy | ||||
| ISSN: | 1178-7007 | ||||
| Official Date: | 2013 | ||||
| Dates: |
|
||||
| Date of first compliant deposit: | 23 December 2015 | ||||
| Volume: | Vol.2013 | ||||
| Number: | No.6 | ||||
| Page Range: | pp. 11-15 | ||||
| DOI: | 10.2147/DMSO.S35053 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Open Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
